Dr. Gardner is world renown drug formulation expert who was formerly the Vice President of Global Pharmaceutical Development, Merck & Co., Inc.; and Former CSO of Transform Pharmaceuticals and J&J Site Head.
Dr. Gardner was born and educated in Scotland, receiving a BSc and Ph.D. in chemistry from the University of Glasgow. After post-doctoral studies at Harvard Medical School (Biophysics) and MIT (Chemical Engineering), he returned to Europe and spent 2 years in the chemistry department at the University of Aberdeen followed by 6 years in drug discovery at the Merrell International Research Center in Strasbourg. Thereafter he joined Merck and Co. in the US, spending the first 4 years as a leader in a drug delivery group. He was then appointed to develop and lead a more effective interface between drug discovery and early pharmaceutical development; he pioneered the paradigm of early intervention which has become the standard in the industry. He progressed in the department to become VP and Global Head of formulation design and development for all Merck products - he was involved in the development of 16 small molecule NCEs whose combined maximum annual sales averaged $20Bn and three major vaccines. In 2001, Colin took early retirement from Merck to become the CSO of a start-up formulation company (TransForm Pharmaceuticals) in the Boston area. Four years later TransForm was acquired by Johnson & Johnson and led to major changes in the way in which J&J integrated discovery and early development. Colin stayed on as the President and Site Leader of TransForm. Colin retired from TransForm/J&J in June 2009 and is now an industry consultant.